Stock Yearly Return 2016
Start date: 12/31/2015
End date: 12/30/2016
Start price/share: $10.72
End price/share: $4.32
Dividends collected/share: $0.00
Total return: -59.70%
Average Annual Total Return: -59.70%
Starting investment: $10,000.00
Ending investment: $4,030.00
Years: 1.00


GENE average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare GENE average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into GENE


Also see:
GENE stock yearly return 2017
GENE stock yearly return 2018
GENE stock yearly return 2019
GENE stock yearly return 2020
GENE YTD return
GENE average annual return 10 years
Genetic Technologies is a molecular diagnostics company that provides predictive testing and assessment tools to help physicians manage women's health. Co.'s key product, BREVAGenplus, was a clinically validated risk assessment test for non-hereditary breast cancer. Co. has launched the first generation BREVAGen test across the United States via its subsidiary Phenogen Sciences Inc. Co. has developed two new cancer risk assessment tests branded as GeneType for Colorectal Cancer and GeneType for Breast Cancer. Co. is developing a polygenic risk score test for COVID-19, which may enable an assessment of the risk of people developing a serious disease should they contract the virus. The GENE stock yearly return is shown above.

The yearly return on the GENE stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2016 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the GENE annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for GENE:
GENE SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Genetic Technologies. (GENE) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

GERN Average Annual Return
GHDX Average Annual Return
GILD Average Annual Return
GKOS Average Annual Return
GLYC Average Annual Return
GMED Average Annual Return
GNCA Average Annual Return
GNMK Average Annual Return
GNMX Average Annual Return
GTHX Average Annual Return
More Healthcare companies »

 

GENE Stock Yearly Return 2016 | www.AverageAnnualReturn.com | Copyright © 2021 - 2021, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.